Probable linagliptin-induced liver toxicity: A case report

Diabetes and Metabolism

Volumn 40, Issue 1, 2014, Pages 82-84

  Kutoh, E ^a,b  

^a Biomedical Center   (Japan)

^b Higashi Totsuka Memorial Hospital   (Japan)

Author keywords

DPP 4 inhibitors; Drug induced liver toxicity; Linagliptin

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; LINAGLIPTIN; LIVER ENZYME;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CASE REPORT; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATOBILIARY PARAMETERS; HUMAN; HYPERTENSION; JAPANESE; JAUNDICE; LINAGLIPTIN INDUCED LIVER TOXICITY; LIVER INJURY; LIVER TOXICITY; MIDDLE AGED; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT;

DPP-4 INHIBITORS; DRUG-INDUCED LIVER TOXICITY; LINAGLIPTIN;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-INDUCED LIVER INJURY; FATIGUE; FEMALE; HALF-LIFE; HUMANS; JAUNDICE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NAUSEA; PURINES; QUINAZOLINES;

EID: 84893806596     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2013.09.009     Document Type: Article

References (14)

1. Drucker D.J., Sherman S.I., Gorelick F.S., Bergenstal R.M., Sherwin R.S., Buse J.B. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 2010, 33:428-433.
2. Richard K.R., Shelburne J.S., Kirk J.K. Tolerability of dipeptidyl peptidase-4 inhibitors: a review. Clin Ther 2011, 33:1609-1629.
3. Forst T., Pfützner A. Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes. Expert Opin Pharmacother 2012, 13:101-110.
4. Neumiller J.J. Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus. Ann Pharmacother 2012, 46:358-367.
5. Fuchs H., Runge F., Held H.D. Excretion of the dipeptidyl peptidase-4 inhibitor linagliptin in rats is primarily by biliary excretion and P-gp-mediated efflux. Eur J Pharm Sci 2012, 45:533-538.
6. Graefe-Mody U., Rose P., Retlich S., Ring A., Waldhauser L., Cinca R., et al. Pharmacokinetics of linagliptin in subjects with hepatic impairment. Br J Clin Pharmacol 2012, 74:75-85.
7. Package insert with linagliptin drug information. http://www.info.pmda.go.jp/go/pack/3969014F1024_1_05.
8. Naranjo C.A., Busto U., Sellers E.M., Sandor P., Ruiz I., Roberts E.A., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981, 30:239-245.
9. Andrade R.J., Robles M., Fernández-Castañer A., López-Ortega S., López-Vega M.C., Lucena M.I. Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. World J. Gastroenterol 2007, 13:329-340.
10. Benichou C., Danan G., Flahault A. Causality assessment of adverse reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993, 46:1331-1336.
11. Itou M., Kawaguchi T., Taniguchi E., Sata M. Dipeptidyl peptidase-4: a key player in chronic liver disease. World J Gastroenterol 2013, 19:2298-2306.
12. Lammert C., Bjornsson E., Niklasson A., Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 2010, 51:615-620.
13. Gross B.N., Cross L.B., Foard J., Wood Y. Elevated hepatic enzymes potentially associated with sitagliptin. Ann Pharmacother 2010, 44:394-395.
14. Toyoda-Akui M., Yokomori H., Kaneko F., Shimizu Y., Takeuchi H., Tahara K., et al. A case of drug-induced hepatic injury associated with sitagliptin. Intern Med 2011, 50:1015-1020.